Expertus Laboratories, INC

Expertus Laboratories, INC was paid $92K by Medicaid between Jan 2018 and Aug 2022, across 38 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 36% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#108 of 225

Median peer was paid$74K

This provider vs. median1.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	3,956	$35K
2019	745	$2K
2020	1,569	$33K
2021	551	$7K
2022	760	$15K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	36%	634	242	$33K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	19%	1,098	580	$18K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	19%	2,632	1,808	$18K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	8.1%	1,500	1,324	$7K
80346		4.5%	12	12	$4K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.8%	158	122	$3K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.1%	177	66	$2K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	1.8%	277	103	$2K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.8%	338	127	$2K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	1.6%	32	30	$1K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	71	44	$831.13
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	88	60	$319.77

26 more codes

87486		<1%	89	$319.77
87581		<1%	89	$319.77
87541		<1%	91	$318.01
87481		<1%	28	$110.08
80363		0%	12	$0.00
80371		0%	12	$0.00
80358		0%	12	$0.00
80345		0%	12	$0.00
80368		0%	12	$0.00
80324		0%	12	$0.00
80320		0%	12	$0.00
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	0%	15	$0.00
80353		0%	12	$0.00
80359		0%	12	$0.00
83992		0%	12	$0.00
80323		0%	12	$0.00
80355		0%	12	$0.00
80336		0%	12	$0.00
80372		0%	12	$0.00
80338		0%	12	$0.00
80366		0%	12	$0.00
80373		0%	12	$0.00
80348		0%	12	$0.00
80356		0%	12	$0.00
80365		0%	12	$0.00
80360		0%	12	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWEIL, JASON (CEO/PRESIDENT)